Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Diltiazem Hydrochloride Extended-Release Capsules USP in strengths of 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg. The drug is used in the treatment of hypertension (high blood pressure), angina (chest pain), and certain heart rhythm disorders. It will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.
The sale of Diltiazem Hydrochloride Capsules is estimated at $191.1 million. The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
